<DOC>
	<DOCNO>NCT00538096</DOCNO>
	<brief_summary>- Evaluate safety tolerability multiple dose MEDI-538 continuous IV infusion 4 8 week adult patient B-cell NHL eligible curative therapy . - Determine maximum tolerate dose MEDI-538 administer continuous IV infusion .</brief_summary>
	<brief_title>A Phase I Study Evaluate Safety , Tolerability Adults With Lymphoma</brief_title>
	<detailed_description>- Evaluate safety tolerability MEDI-538 dose 5 , 10 , 15 μg/m2/24h continuous IV infusion 4 8 week adult patient B-cell NHL eligible - Determine MTD MEDI-538 administer continuous IV infusion 4 8 week adult patient B-cell NHL eligible curative therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Adult men woman least 18 year age ; Written inform consent Heath Insurance Portability Accountability Act ( HIPAA ) authorization ( applies cover entity US ) obtain patient prior perform studyrelated procedure , include screen visit ; Histologically confirm Bcell NHL one follow classification : Follicular lymphoma Marginal zone lymphoma ; Lymphoplasmocytic lymphoma ; Mantle cell lymphoma . Not eligible curative therapy accord NCCN guideline NHL ( NCCN 2006 ) ; Measurable disease ( least one lesion ≥ 20 mm one dimension ) document compute tomography ( CT ) scan ; Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( see Appendix A ) ; Life expectancy least 6 month ; Heterosexual sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral implanted contraceptive , intrauterine device , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 21 day prior first dose study drug , must agree continue use precaution 3 month last dose MEDI538 . Cessation birth control point discuss responsible physician . Heterosexual sexually active male , unless surgically sterile , must likewise use effective method birth control ( condom ) must agree continue use precaution 3 month last dose MEDI538 ; Hemoglobin ≥ 10.0 g/dL ; absolute neutrophil count ( ANC ) ≥ 1.5 × 10^9/L ; platelet ≥ 100.0 × 10^9/L ; lymphocyte count ≥ 0.8 × 10^9/L ; leukocyte count ≥ 3.0 × 10^9/L ; Ddimer ≤ 2.5 × upper limit normal ( ULN ) ; antithrombin III ≥ low limit normal ( LLN ) ; 10 . Total bilirubin ≤ 1.5 × ULN ; aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , amylase lipase ≤ 2 × ULN ; serum creatinine ≤ 2 × ULN , creatinine clearance ≥ 50 mL/min . Receipt MEDI538 previous clinical study ; History allergy reaction component MEDI538 formulation ; Any NHL list inclusion criterion 3 ; History malignancy Bcell NHL within 5 year prior study entry , exception basal cell carcinoma skin carcinoma situ cervix successfully treat curative therapy ; Known suspect CNS involvement NHL ; Clinical history significant CNS pathology , eg , multiple occurrence confusion , dementia , multiple previous infarct , major brain surgery ; Active infection know bacteremia . Patients document evidence culture positive sepsis active infection require IV antibiotic therapy must complete full course antibiotic treatment clinical laboratory evidence bacterial infection least 2 week prior start therapy MEDI538 . Vaccination ( either preventive therapeutic infectious disease cancer ) within 2 week prior initiation study drug ; Infection human immunodeficiency virus ( HIV1 HIV2 ) , chronic infection hepatitis B C , acute infection hepatitis A ; History primary immunodeficiency ; History serious , chronic autoimmune disease , eg , rheumatoid arthritis , systemic lupus erythematosus , multiple sclerosis ; Elective surgery plan study period 30 day discontinuation MEDI538 ; Autologous stem cell transplantation within 26 week prior study entry ; Allogenic stem cell transplantation solid organ transplant ; Cancer chemotherapy within 6 week prior study entry ; Radiotherapy within 6 week prior study entry ; Receipt investigational agent within 12 week prior initiation study drug ; Treatment rituximab within 12 week prior study entry ; Prior treatment alemtuzumab ; Regular dose systemic corticosteroid 4 week prior initiation study drug anticipate need corticosteroid exceed prednisone 20 mg/day equivalent trial , systemic immunosuppressive therapy within 4 week prior study entry ; Any contraindication chronic anticoagulation lowmolecular weight heparin ( LMWH ) ; Inability safe placement prolong use ( least 8 week ) central venous catheter ; Contraindication protocolspecified concomitant medication ( methylprednisolone , antacid , antihistamine ) study ; Presence human antimurine antibody know hypersensitivity immunoglobulin ; Pregnancy ( sexually active female childbearing potential must negative urine pregnancy test day first dose study drug , prior dose ) nursing ; Evidence uncontrolled systemic disease ( Bcell NHL ) , find upon physical examination history disease , opinion investigator medical monitor , may compromise safety patient study confound analysis study ; Inability meet social environment requirement outpatient therapy ( see Section 3.3.4.4 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>B-cell Non-Hodgkin 's Lymphoma</keyword>
</DOC>